Genitourinary Cancers | Specialty

Therapeutic Options in Metastatic CRPC

June 1st 2016

Safety of Low-Dose Steroids with Abiraterone in Prostate Cancer

June 1st 2016

Potential Predictive Markers in Prostate Cancer

June 1st 2016

Candidacy for Chemotherapy in Oligometastatic Prostate Cancer

June 1st 2016

Local and Systemic Therapeutic Options in Low-Volume Prostate Cancer

June 1st 2016

Combining Radium-223 With Other Therapies in Prostate Cancer

June 1st 2016

Factors Impacting Treatment Approach in Advanced Prostate Cancer

June 1st 2016

Defining Symptomatic in Prostate Cancer

June 1st 2016

Treatment of Bone Metastases in Prostate Cancer

June 1st 2016

Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma

May 31st 2016

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

Dr. Funahashi on Enhanced Activity With Lenvatinib/Everolimus Combo in RCC

May 27th 2016

Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Dr. Stanley Yap on Sequential Therapy for Muscle-Invasive Bladder Cancer

May 27th 2016

Stanley Yap, MD, assistant professor, urologic oncology, UC Davis Comprehensive Cancer Center, discusses sequential therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Expert Explains Role for Newly Approved TKI/mTOR Combo in RCC

May 25th 2016

Sumanta Kumar Pal, MD, provides insight on the FDA approval of the TKI lenvatinib in combination with everolimus, an mTOR inhibitor as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

Dr. Pili on Significance of Entinostat/IL-2 Study in RCC

May 25th 2016

Roberto Pili, MD, professor of Medicine and Robert Wallace Miller Professor of Oncology at Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, discusses the significance of the preliminary results of a phase I/II study, which examined the combination of the HDAC inhibitor entinostat and high-dose interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (RCC) of clear cell histology.

Frontline Cabozantinib Improves PFS in Renal Cell Carcinoma

May 23rd 2016

Cabozantinib (Cabometyx) significantly improved progression-free survival compared with sunitinib (Sutent) in treatment-naive patients with advanced renal cell carcinoma in the phase II CABOSUN trial.

Next Steps With Obesity-Related Genes in Patients With RCC

May 23rd 2016

Julia R. Mendoza-Perez, PhD, visiting scientist, Epidemiology, The University of Texas MD Anderson Cancer Center, discusses next steps and research regarding obesity-related genes in patients with renal cell carcinoma (RCC).

Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer

May 19th 2016

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.

FDA Approves Atezolizumab in Bladder Cancer

May 18th 2016

The FDA granted the PD-L1 inhibitor atezolizumab (Tecentriq) an accelerated approval as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-based chemotherapy, either before or after surgery.

Dr. Choueiri on FDA Approval of Lenvatinib Plus Everolimus in RCC

May 13th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of the combination of lenvatinib (Lenvima) and everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy.

FDA Approves Lenvatinib/Everolimus for Advanced RCC

May 13th 2016

The FDA has approved the combination of lenvatinib and everolimus as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy